NAGE — Niagen Bioscience, Inc.
—
Nasdaq ·
Materials ·
Chemicals ·
CIK 1386570 ·
Last close
$2.66
Market Cap
$210.48M
52W High
$7.95
52W Low
$2.61
ADV30
486,134
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 29,785,000 | 19,314,000 | 700,000 | 963,000 | 106,589,000 | 66,740,000 | 24,061,000 |
| Mar 2026 | 31,474,000 | 19,976,000 | 1,576,000 | 6,318,000 | 114,329,000 | 66,397,000 | 31,999,000 |
| Dec 2025 | 33,839,000 | 21,704,000 | 2,103,000 | 4,132,000 | 106,406,000 | 64,636,000 | 29,873,000 |
| Sep 2025 | 33,986,000 | 21,928,000 | 4,236,000 | 4,578,000 | 98,139,000 | 64,138,000 | 27,463,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$5,949,000
Investing CF
$5,028,000
Financing CF
$-4,711,000
CapEx
$-275,000
Dividends Paid
—
Buybacks
$-5,121,000
EPS Diluted TTM
$0.18
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-157,247,000
Inventory
$20,640,000
Receivables
$8,580,000
ST Investments
—
EBIT TTM
$8,615,000
Pretax Income TTM
$17,028,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$129,084,000
EBITDA
$9,591,000
Free Cash Flow
$1,641,375
Enterprise Value
$176,791,728
Total Cash
$66,588,000
Total Debt
$2,329,000
Shares Out
79,126,002
Trailing EPS
$0.19
Book Value
$1.04
ROE
21.8%
ROA
5.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 129,423,000 | 14,296,000 | 17,382,000 | 106,406,000 | 29,873,000 | 76,533,000 | 13,504,000 |
| Dec 2024 | 99,597,000 | 7,726,000 | 8,550,000 | 68,278,000 | 22,184,000 | 46,094,000 | 12,109,000 |
| Dec 2023 | 83,570,000 | -5,599,000 | -4,938,000 | 54,964,000 | 26,508,000 | 28,456,000 | 7,117,000 |
| Dec 2022 | 72,050,000 | -18,628,000 | -16,540,000 | 54,057,000 | 25,385,000 | 28,672,000 | -15,098,000 |
TTM Snapshot
Revenues TTM
$130,416,000
NetIncome TTM
$18,637,000
OpCashFlow TTM
—
Assets (Latest)
$114,329,000
Forward EPS
$0.10
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LTBR | LIGHTBRIDGE Corp | $211.77M | $6.01 | — |
| CRLBF | Cresco Labs Inc. | $226.15M | $0.64 | — |
| FF | FutureFuel Corp. | $227.21M | $5.18 | — |
| LODE | Comstock Inc. | $167.94M | $2.21 | — |
| USNA | USANA HEALTH SCIENCES INC | $270.87M | $14.66 | — |
News headlines (Yahoo Finance, 1h cache)
Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for
2026-10-08 12:32 · Yahoo
Niagen Bioscience to Present at LD Micro 20th Annual Main Event
2026-10-06 12:32 · Yahoo
Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®" a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater
2026-10-01 12:32 · Yahoo
Niagen Bioscience (NAGE): Can Its NAD+ Business Drive the Next Leg of Growth?
2026-09-30 16:59 · Yahoo
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
2026-09-30 12:32 · Yahoo
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
2026-09-17 12:32 · Yahoo
Niagen Bioscience to Present at Longevity Investors Conference
2026-09-02 12:32 · Yahoo
Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
2026-08-26 12:32 · Yahoo
Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
2026-08-12 12:32 · Yahoo
Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
2026-08-06 12:34 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.